Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Steven Coutre, Wyndham H. Wilson, Maryalice Stetler-Stevenson, David J. FitzGerald, Linda Santiago, Guozhi Gao, Mark C. Lanasa, Ira Pastan

Blood (2018) 131 (21): 2331–2334.

https://doi.org/10.1182/blood-2017-09-803072

Published: 2018

Includes: Supplemental data

Journal Articles

Targeted diphtheria toxin to treat BPDCN

David J. FitzGerald

Blood (2014) 124 (3): 310–312.

https://doi.org/10.1182/blood-2014-06-578633

Published: 2014

Journal Articles

Immunotoxins for leukemia

Alan S. Wayne, David J. FitzGerald, Robert J. Kreitman, Ira Pastan

Blood (2014) 123 (16): 2470–2477.

https://doi.org/10.1182/blood-2014-01-492256

Published: 2014

Journal Articles

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

Waleed Haso, Daniel W. Lee, Nirali N. Shah, Maryalice Stetler-Stevenson, Constance M. Yuan, Ira H. Pastan, Dimiter S. Dimitrov, Richard A. Morgan, David J. FitzGerald, David M. Barrett, Alan S. Wayne, Crystal L. Mackall, Rimas J. Orentas

Blood (2013) 121 (7): 1165–1174.

https://doi.org/10.1182/blood-2012-06-438002

Published: 2013

Includes: Supplemental data

Journal Articles

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Alan S Wayne, MD, Deepa Bhojwani, MD, Lewis B. Silverman, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PhD, Nirali N Shah, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Manuela Buzoianu, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Ramy Ibrahim, MD, Ira Pastan, MD

Blood (2011) 118 (21): 248.

https://doi.org/10.1182/blood.V118.21.248.248

Published: 2011

Journal Articles

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

Robert J. Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H. Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert J. Lechleider, MD, Ira Pastan, MD

Blood (2010) 116 (21): 2516.

https://doi.org/10.1182/blood.V116.21.2516.2516

Published: 2010

Journal Articles

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

Alan Wayne, MD, Deepa Bhojwani, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PHD, Lewis B. Silverman, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Jennifer McDevitt, PharmD, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Robert J. Lechleider, MD, Ira Pastan, MD

Blood (2010) 116 (21): 3246.

https://doi.org/10.1182/blood.V116.21.3246.3246

Published: 2010

Journal Articles

Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).

Alan S. Wayne, MD, Deepa Bhojwani, MD, Sima Jeha, MD, Maryalice Stetler-Stevenson, MD, PhD, Ching-Hon Pui, MD, Jennifer McDevitt, PharmD, PhD, David J. FitzGerald, Robert J Kreitman, MD, Karen Kaucic, MD, Ira Pastan

Blood (2009) 114 (22): 839.

https://doi.org/10.1182/blood.V114.22.839.839

Published: 2009

Journal Articles

Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.

Robert J Kreitman, MD, Wyndham H Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Ira Pastan, MD

Blood (2009) 114 (22): 3442.

https://doi.org/10.1182/blood.V114.22.3442.3442

Published: 2009

Journal Articles

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

Robert J Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert Lechleider, MD, Karen Kaucic, MD, Ira Pastan, MD

Blood (2009) 114 (22): 888.

https://doi.org/10.1182/blood.V114.22.888.888

Published: 2009

Journal Articles

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity

John E. Weldon, Laiman Xiang, Oleg Chertov, Inger Margulies, Robert J. Kreitman, David J. FitzGerald, Ira Pastan

Blood (2009) 113 (16): 3792–3800.

https://doi.org/10.1182/blood-2008-08-173195

Published: 2009

Journal Articles

Interim Phase I Results of Recombinant Immunotoxin HA22 in Patients with Hairy Cell and Chronic Lymphocytic Leukemias

Robert J. Kreitman, MD, Wyndham H. Wilson, Maryalice Stetler-Stevenson, Pierre Noel, David J FitzGerald, Ira Pastan

Blood (2008) 112 (11): 3160.

https://doi.org/10.1182/blood.V112.11.3160.3160

Published: 2008

Journal Articles

Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors

Elizabeth Mansfield, Peter Amlot, Ira Pastan, David J. FitzGerald

Blood (1997) 90 (5): 2020–2026.

https://doi.org/10.1182/blood.V90.5.2020

Published: 1997

NARROW

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Targeted diphtheria toxin to treat BPDCN

Immunotoxins for leukemia

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).

Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity

Interim Phase I Results of Recombinant Immunotoxin HA22 in Patients with Hairy Cell and Chronic Lymphocytic Leukemias

Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only